Approval · Notice of Compliance 33656 · 2024
AMLODIPINE: Notice of Compliance 33656
Issued July 16, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33656
- Date
- July 16, 2024
- Company
- Altamed PharmaBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement between two manufacturers
- Canadian reference product
- NORVASC (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AMLODIPINE | 02490781 | Marketed |
| AMLODIPINE | 02490803 | Marketed |
| AMLODIPINE | 02490811 | Marketed |
Medicinal ingredients
- AMLODIPINE 2.5 MG per TAB
- AMLODIPINE 5 MG per TAB
- AMLODIPINE 10 MG per TAB